Tanoira Cassagne advises SAVANT PHARM

News

Tanoira Cassagne advises SAVANT PHARM

shutterstock_mercado_de_capitales_2

Tanoira Cassagne Abogados advised SAVANT PHARM S.A. (the “Company”), in the updating of the Company’s Global Notes Program for an amount up to V/N $500,000,000 (or its equivalent in other currencies) and in the issuance in the local market of the Series VI Class “L” Notes for a total aggregate amount of $180,000,000.- and Series VI Class “M” Dollar Linked Notes for a total aggregate amount of U$S 1,434,252.-(at the Initial Exchange Rate) (the “Notes”).

The placement of the Notes took place on June 26, 2020 with Trust Capital S.A. as Arranger and Placement Agent, together with AR Partners S.A. as Placement Agent for the Notes, constituting a new issuance of Notes made 100% remotely within the framework of the emergency situation unleashed by the COVID-19. The Notes were issued on June 30, 2020.

The Class “L” Notes, $180,000,000.- (Pesos one hundred and eighty million) are due on June 30, 2021, with a variable interest rate consisting of the Badlar Rate plus a cut-off margin of 4.88%, as a result of the bidding process. Interest payable on a quarterly basis.

The Class “M” Notes, U$S 1,434,252 (U.S. Dollars one million four hundred and thirty-four thousand two hundred and fifty-two), are due on June 30, 2022, with a fixed nominal annual interest rate of 0% as result of the bidding process. Interest payable on a quarterly basis. Class “M” Notes will be paid in Pesos at the applicable exchange rate.

The Company’s principal activity is the manufacture and marketing of drugstore, pharmaceutical and medicinal products.

The Company’s Notes have been authorized for listing and negotiating on the Bolsas y Mercados Argentinos S.A. (BYMA) and Mercado Abierto Electrónico S.A. (MAE) respectively.

Legal counsel on the transaction.

Tanoira Cassagne Abogados: Through its team led by its Partners Alexia Rosenthal and Jaime Uranga, and Associates Juan Sanguinetti and Mariana Troncoso.